Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2016', provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - The report reviews pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) therapeutics and enlists all their major and minor projects - The report assesses End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Overview 6 Therapeutics Development 7 Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview 7 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics under Development by Companies 8 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Products under Development by Companies 12 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development 13 Acceleron Pharma, Inc. 13 Bayer AG 14 BioAegis Therapeutics, Inc. 15 F. Hoffmann-La Roche Ltd. 16 Ionis Pharmaceuticals, Inc. 17 Prolong Pharmaceuticals, LLC 18 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 calcium succinate - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 IONIS-FXIRx - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 obinutuzumab - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 rivaroxaban - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Sanguinate - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 sotatercept - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 TNT-009 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Recent Pipeline Updates 45 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects 69 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products 70 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones 71 Featured News & Press Releases 71 Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 71 Nov 13, 2014: Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014 71 Apr 23, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis 71 Mar 17, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting 72 Dec 18, 2013: Acceleron Earns $7 Million Milestone Payment for Celgene's Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis 73 Appendix 75 Methodology 75 Coverage 75 Secondary Research 75 Primary Research 75 Expert Panel Validation 75 Contact Us 75 Disclaimer 76
List of Tables
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Acceleron Pharma, Inc., H1 2016 13 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Bayer AG, H1 2016 14 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics, Inc., H1 2016 15 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 16 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 17 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Prolong Pharmaceuticals, LLC, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics - Recent Pipeline Updates, H1 2016 45 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H1 2016 69 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, H1 2016 70
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
